Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro), a stabilized analog of the endogenous immunopeptide tuftsin, and the published record describes it acting through several interlocking mechanisms rather than through a single receptor. Most of that mechanistic evidence is preclinical, drawn from rodent studies and a smaller body of Russian clinical work, so the pathways are well characterized in animals and plausible but less firmly established in humans.
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) and stabilized tuftsin analog documented as a multi-target neuropeptide that modulates GABAergic and serotonergic signaling, BDNF-linked gene expression, enkephalin stability, and immune cytokines, with the mechanistic evidence drawn overwhelmingly from preclinical animal models.
Selank's first four residues are tuftsin itself, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the CH2 domain of the immunoglobulin G heavy chain, while the appended Pro-Gly-Pro tripeptide is the deliberate engineering step developed at the Institute of Molecular Genetics with the Zakusov Institute of Pharmacology in Russia. Native tuftsin is stripped by aminopeptidases within minutes, so the proline-rich extension, which resists exopeptidase attack because peptide bonds adjacent to proline are poor substrates for many peptidases, is what converts an ephemeral endogenous signal into a molecule stable enough to reach the nervous system.
The proline-rich Pro-Gly-Pro extension appended to the tuftsin tetrapeptide blocks aminopeptidase cleavage, converting native tuftsin's half-life of minutes into a molecule stable enough to express central nervous system activity that tuftsin alone does not meaningfully show.
The published record describes Selank influencing the GABAergic system indirectly, not by binding GABA receptors the way a benzodiazepine binds the GABA-A complex. Rodent studies report shifted expression of genes associated with inhibitory neurotransmission and altered GABAergic activity in anxiety-related brain regions, raising inhibitory tone as a dose-dependent nudge rather than clamping it open.
Selank is reported to raise GABAergic inhibitory tone indirectly, through changes in gene expression and system-level balance rather than direct binding at the GABA-A receptor, a mechanism documented mainly in preclinical rodent studies.
Among the more reproducible preclinical findings, Selank raises serotonin metabolism in the brain: rodent studies measured higher 5-hydroxyindoleacetic acid (5-HIAA) and an elevated 5-HIAA-to-serotonin ratio, read as accelerated serotonergic turnover. These shifts were reported within minutes of administration in animals, far faster than the multi-week onset of serotonin-reuptake antidepressants, which reflects action on turnover and metabolism rather than reuptake blockade.
In rodent studies Selank raised serotonin turnover within minutes of administration, measured as increased 5-HIAA and a higher 5-HIAA-to-serotonin ratio, a metabolism-driven mechanism distinct from the reuptake blockade of SSRIs.
Rodent work reports Selank altering expression of brain-derived neurotrophic factor (BDNF), a signaling protein central to neuronal survival, synaptic plasticity, and the growth of new connections, with changes in BDNF messenger RNA in the hippocampus under both single and repeated dosing. Broader transcriptomic analyses describe it shifting a wider set of genes, an interpretation consistent with a slower reshaping of the cellular environment toward plasticity rather than moment-to-moment receptor signaling.
Rodent studies report Selank altering hippocampal BDNF messenger RNA and a broader set of plasticity- and immune-related genes, a transcriptional mechanism that plausibly underlies benefits building over repeated use, though its human relevance is not yet established.
Enkephalins are short endogenous opioid peptides that regulate pain perception, mood, and stress, and peptidases in the aminopeptidase family normally degrade them within minutes. Selank has been reported to inhibit that enzymatic degradation, prolonging and amplifying the body's own enkephalin signaling rather than introducing an external agonist, so the effect stays bounded by the amount the body itself produces.
| Criteria | Selank (enkephalin stabilization) | Direct opioid agonist |
|---|---|---|
| Point of action | Slows enkephalin-degrading peptidases | Floods opioid receptors with an exogenous ligand |
| Ceiling | Bounded by endogenous enkephalin output | Set by the dose administered |
| Dependence pattern | Not associated with reward-driven dependence | Reward-driven dependence typical |
Selank is reported to inhibit enkephalin-degrading peptidases, raising endogenous opioid tone in a bounded, self-limiting way rather than acting as an exogenous agonist, a biochemical mechanism supported almost entirely by preclinical data.
Because its core is tuftsin, a peptide the immune system produces to stimulate phagocytosis and immune-cell activity, Selank carries measurable immunomodulatory properties alongside its central effects. Reported actions include shifts in the balance of cytokines and interferons, pointing toward a regulatory rather than a broadly stimulating or suppressing influence, though the peptide is engineered and studied primarily for the nervous system.
Selank retains tuftsin-derived immunomodulatory activity, reported as regulatory shifts in cytokine and interferon signaling, but this dimension is documented as secondary to its anxiolytic and neurotropic profile.
Selank is most often delivered as an intranasal solution because peptides are poorly suited to oral dosing, where stomach acid and digestive proteases would destroy them before absorption. The nasal route offers rapid uptake and a shorter path toward the central nervous system, and even with its proline-rich stabilization the peptide has a comparatively short residence time before ordinary peptide catabolism clears it.
Selank is administered intranasally to bypass gastrointestinal degradation, distributes with central effects detectable within minutes, and is cleared through ordinary peptide catabolism without accumulation, which is why the studied dosing relies on repeated administration rather than a single long-acting dose.
The central difference is the point of action: benzodiazepines bind a specific site on the GABA-A receptor complex and directly potentiate chloride-channel opening, producing strong, immediate inhibition that also carries sedation, muscle relaxation, and, with repeated use, tolerance and physical dependence. Selank does not bind that site; it modulates the GABAergic and serotonergic systems diffusely through gene expression, neurotransmitter turnover, and peptide stabilization, nudging the brain's inhibitory balance rather than forcing it.
| Criteria | Selank | Benzodiazepines |
|---|---|---|
| Mechanism | Diffuse modulation via gene expression and turnover | Direct binding at the GABA-A receptor site |
| Effect strength | Milder, regulatory nudge | Strong, immediate inhibition |
| Sedation and impairment | Reported without marked sedation or motor impairment | Sedation, cognitive dulling, motor impairment |
| Dependence | No comparable withdrawal or dependence profile | Tolerance and physical dependence with repeated use |
Unlike benzodiazepines, which bind the GABA-A receptor to force chloride-channel opening, Selank modulates inhibitory balance diffusely and produces anxiolysis without the marked sedation, tolerance, or dependence of benzodiazepines, though much of the direct comparison rests on Russian clinical and preclinical work.
Educational use only. This article describes what the published scientific and clinical literature reports about Selank. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
